Ask patients to reframe the readings as a call to action, a signal to tweak, to fine-tune.
The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management.
How can we harness the electronic resources we already have at our disposal—and use them to help everyone better engage?
Is GLP-1 part of the answer to why cardiac mortality tends to be higher in diabetes patients treated with intensive glycemic control?
Five studies on the impact of diabetes drugs on CV outcomes get the editors' nod for the most promising results in 2017 diabetes research. Find out which 5!
Insulin pump/sensor combos, continuous glucose sensors . . . a wrap-up of these and other advances in endocrinology in 2017, plus some caveats for the future.
ShugaTrak, Glucose Buddy, OnTrack -- 3 of the 5 apps we highlight that are designed to make diabetes monitoring seamless for all.
More intensive reduction of A1c, lipids, and blood pressure did, however, result in a significantly reduced rate of cerebrovascular events.
What's true and what's false about the connections between these often comorbid conditions? These 10 statements will test what you know.
Data from the DPP Outcomes Study reveal a greater than 25% increase in risk for diabetes in this already vulnerable population.
Five slides, 5 snapshots of products that help reduce fingerstick anxiety, enhance medication adherence, and prevent plantar ulcers.
A recent study, the first of its kind, reports an association between T1DM and AF, and between glycemic control and AF. Plus, there are interesting gender differences.
Guidelines say metformin should be stopped where there is acute kidney injury or risk of renal compromise. Now there is evidence to support those recommendations.
To image or not to image: A new study validates professional society recommendations on follow-up strategies for adrenal masses.
The AACE/ACE 2017 recommendations on lipid management renew focus on LDL-C targets, and go far lower than any group has ventured to date.